Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2016

ASH 2016: Multiple myeloma highlights

Prof Marivi Mateos, Prof Philippe Moreau, Prof Saad Usmani, Prof Heinz Ludwig

ASH 2016: Multiple myeloma highlights ( Prof Marivi Mateos, Prof Philippe Moreau, Prof Saad Usmani, Prof Heinz Ludwig )

Interim results from the ZUMA-1 trial of novel CAR-T cells against non-Hodgkin lymphoma

Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA

Interim results from the ZUMA-1 trial of novel CAR-T cells against non-Hodgkin lymphoma ( Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )

Pacritinib versus best available therapy for low platelet Myelofibrosis

Dr John Mascarenhas - Mount Sinai School of Medicine New York, USA

Pacritinib versus best available therapy for low platelet Myelofibrosis ( Dr John Mascarenhas - Mount Sinai School of Medicine New York, USA )

Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL

Dr Zanetta Lamar - Wake Forest Baptist Medical Center, Winston-Salem, USA

Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL ( Dr Zanetta Lamar - Wake Forest Baptist Medical Center, Winston-Salem, USA )

DVd vs Vd for relapsed or refractory myeloma: CASTOR trial update

Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain

$DVd vs Vd for relapsed or refractory myeloma: CASTOR trial update ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )$

ASH 2016 highlights: breaking new ground in haematology

Dr Giovanni Martinelli - Università di Bologna, Bologna, Italy

ASH 2016 highlights: breaking new ground in haematology ( Dr Giovanni Martinelli - Università di Bologna, Bologna, Italy )

TCA cycle inhibition by CPI-613 increases chemo sensitivity in older AML patients

Dr Timothy Pardee - Wake Forest Baptist Medical Center, Winston-Salem, USA

TCA cycle inhibition by CPI-613 increases chemo sensitivity in older AML patients ( Dr Timothy Pardee - Wake Forest Baptist Medical Center, Winston-Salem, USA )

Azacitidine plus nivolumab against acute myeloid leukaemia

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA

Azacitidine plus nivolumab against acute myeloid leukaemia ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )

IKZF1 mutations associated with paediatric ALL

Dr Michelle Churchman - St. Jude Children's Research Hospital, Memphis, USA

IKZF1 mutations associated with paediatric ALL ( Dr Michelle Churchman - St. Jude Children's Research Hospital, Memphis, USA )

Rituximab after ASCT prolongs survival for young MCL patients

Prof Steven Le Gouill - Nantes Medical University, Nantes, France

Rituximab after ASCT prolongs survival for young MCL patients ( Prof Steven Le Gouill - Nantes Medical University, Nantes, France )

How can we use crenolanib to treat AML?

Dr Eunice Wang - Roswell Park Cancer Institute, New York, USA

How can we use crenolanib to treat AML? ( Dr Eunice Wang - Roswell Park Cancer Institute, New York, USA )

Highlights in myeloid leukaemia research from ASH 2016

Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy

Highlights in myeloid leukaemia research from ASH 2016 ( Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy )

Thromboembolytic risks of central venous catheters in paediatric patients

Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA

Thromboembolytic risks of central venous catheters in paediatric patients ( Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA )

Pure erythroid leukaemias

Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA

Pure erythroid leukaemias ( Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA )

Clinical updates for guadecitabine and vorinostat

Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA

Clinical updates for guadecitabine and vorinostat ( Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA )

ALL: Combining paediatric-type therapy with minimal residual disease

Dr Alessandro Rambaldi - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

ALL: Combining paediatric-type therapy with minimal residual disease ( Dr Alessandro Rambaldi - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy )

Pracinostat and azacitidine for elderly AML

Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA

Pracinostat and azacitidine for elderly AML ( Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA )

ASH 2016: AML, CLL and leukaemogenesis latest

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

ASH 2016: AML, CLL and leukaemogenesis latest ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )

Advances in CLL from ASH 2016

Prof Stephan Stilgenbauer, Prof Clemens-Martin Wendtner, Prof Steven Coutre And Dr Jeffery Jones

Advances in CLL from ASH 2016 ( Prof Stephan Stilgenbauer, Prof Clemens-Martin Wendtner, Prof Steven Coutre And Dr Jeffery Jones )

Ineligibility required for 'anti-trials': inclusion in studies regardless of fitness

Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA

Ineligibility required for 'anti-trials': inclusion in studies regardless of fitness ( Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA )

Vosaroxin for relapsed AML: Updates from VALOR

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

Vosaroxin for relapsed AML: Updates from VALOR ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )

Impact of next-generation sequencing on treatment choice for MDS

Dr Ana Alfonso Pierola - MD Anderson Cancer Center, Houston, USA

Impact of next-generation sequencing on treatment choice for MDS ( Dr Ana Alfonso Pierola - MD Anderson Cancer Center, Houston, USA )

Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial

Dr Andrew Davies - University of Southampton, Southampton, UK

Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial ( Dr Andrew Davies - University of Southampton, Southampton, UK )

Venetoclax plus cytarabine in elderly AML patients

Dr Andrew Wei - Alfred Hospital, Melbourne, Australia

Venetoclax plus cytarabine in elderly AML patients ( Dr Andrew Wei - Alfred Hospital, Melbourne, Australia )

Intravenous or subcutaenous rituximab for FL in the SABRINA study

Dr Andrew Davies - University of Southampton, Southampton, UK

Intravenous or subcutaenous rituximab for FL in the SABRINA study ( Dr Andrew Davies - University of Southampton, Southampton, UK )

Ibrutinib in CLL: RESONATE and resistance

Dr Jennifer Woyach - The Ohio State University Medical Center, Columbus, USA

Ibrutinib in CLL: RESONATE and resistance ( Dr Jennifer Woyach - The Ohio State University Medical Center, Columbus, USA )

Large granular lymphocyte proliferations in MDS

Dr Christa Roe - H. Lee Moffitt Cancer Center, Tampa, USA

Large granular lymphocyte proliferations in MDS ( Dr Christa Roe - H. Lee Moffitt Cancer Center, Tampa, USA )

Durable remissions with the VcR-CVAD regimen for MCL regardless of age

Dr Julie Chang - University of Wisconsin Hospital and Clinics, Madison, USA

Durable remissions with the VcR-CVAD regimen for MCL regardless of age ( Dr Julie Chang - University of Wisconsin Hospital and Clinics, Madison, USA )

Tailoring therapy for leukaemia patients

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Tailoring therapy for leukaemia patients ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )

TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial

Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France

TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )

Dose reduction of TKIs for CML patients with deep molecular response

Prof Mhairi Copland - University of Glasgow, Glasgow, UK

Dose reduction of TKIs for CML patients with deep molecular response ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )

Updates from the EURO-SKI trial of tyrosine kinase cessation

Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France

Updates from the EURO-SKI trial of tyrosine kinase cessation ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )

Incidence and risk factors for central venous catheter related thrombosis in children

Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA

Incidence and risk factors for central venous catheter related thrombosis in children ( Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA )

CML patients with stable response may safely decrease dose of TKI

Prof Mhairi Copland - University of Glasgow, Glasgow, UK

CML patients with stable response may safely decrease dose of TKI ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )

Novel antibody boosts responses in newly diagnosed AML

Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA

Novel antibody boosts responses in newly diagnosed AML ( Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA )

Vadastuximab talirine in combination for newly diagnosed AML

Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA

Vadastuximab talirine in combination for newly diagnosed AML ( Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA )

Remissions following anti-CD22 CAR therapy in children with relapsed ALL

Dr Terry Fry - National Cancer Institute, Bethesda, USA

Remissions following anti-CD22 CAR therapy in children with relapsed ALL ( Dr Terry Fry - National Cancer Institute, Bethesda, USA )

Subgroup analysis of elderly high risk AML patients receiving CPX-351

Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA

Subgroup analysis of elderly high risk AML patients receiving CPX-351 ( Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )

A new spin on leukaemia therapy

Prof Armand Keating - University of Toronto, Toronto, Canada

A new spin on leukaemia therapy ( Prof Armand Keating - University of Toronto, Toronto, Canada )

Anti CD22 CAR T cell therapy for relapsed paediatric ALL

Dr Nirali Shah - National Cancer Institute, Bethesda, USA

Anti CD22 CAR T cell therapy for relapsed paediatric ALL ( Dr Nirali Shah - National Cancer Institute, Bethesda, USA )

CPX-351 after stem cell transplant for elderly patients with AML

Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA

CPX-351 after stem cell transplant for elderly patients with AML ( Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )

More from ecancer